Synergistic technology platforms being leveraged to accelerate development of high value ingredients
SEATTLE (October 20, 2020) - Arzeda, the Protein Design Company™, today announced that the company has entered into a joint development agreement with Amyris that leverages the complementary nature of the two companies’ technology platforms to accelerate the development and commercialization of high value ingredients. This marks the second joint project between the parties. Amyris and Arzeda collaborated successfully on a Defense Advanced Research Projects Agency (DARPA) Technology Investment Agreement (TIA) during the period of 2015 – 2019.
The objective of this Development Collaboration Agreement is for Arzeda to design and develop novel enzymes for Amyris with unique functionalities, which Amyris will incorporate into their fermentation process to facilitate production of the target high value ingredients. Funding of the project is milestone based, with Arzeda receiving an additional payment contingent on early success as well as a value-share on product commercialization. Enzymes being designed and developed by Arzeda for this project are not found in nature and thus represent the power of the computational platform to build enzymes with unique functionality without a natural starting point. Amyris and Arzeda expect to have fermentation strains containing enzymes designed by Arzeda developed during 2021.
“We are very excited to again work with Amyris on bringing new products to market by combining protein design and strain engineering,” said Alexandre Zanghellini, Arzeda CEO. “Amyris is a pioneer of synthetic biology, and our previous collaboration gave us tremendous respect for their technical competency and professionalism. We witnessed how Amyris’ technology platform can dramatically accelerate the development of products that incorporate Arzeda’s designer enzymes and proteins, and we are looking forward to this new commercial partnership.”
Sunil Chandran, Senior Vice President R&D for Amyris, added, “We saw firsthand in our previous work with Arzeda the power of combining physics-based computational protein design, machine learning and rapid experimental testing to access new enzyme functionality. We look forward to deploying their unique technology platform and expertise to further accelerate Amyris’ product development.”
Since 2008 Arzeda has been harnessing the power of computational protein design to create and manufacture proteins that enhance our lives and protect our planet. In partnership with Fortune 500 companies and industrial leaders, we develop healthy and sustainable products with a clear path to access the food ingredients industry globally. Arzeda's proprietary protein design platform combines physics-based computational protein design, machine learning and lab automation to expand the reach of biotechnology beyond the solutions that nature evolved. For more information, please visit www.arzeda.com.
Amyris (Nasdaq: AMRS) is a science and technology leader in the research, development and production of sustainable ingredients for the Clean Health & Beauty and Flavors & Fragrances markets. Amyris uses an impressive array of exclusive technologies, including state-of-the-art machine learning, robotics and artificial intelligence. Our ingredients are included in over 3,000 products from the world's top brands, reaching more than 200 million consumers. Amyris is proud to own three consumer brands - all built around its No Compromise® promise of clean ingredients: Biossance™ clean beauty skincare, Pipette™ clean baby skincare and Purecane™, a zero-calorie sweetener naturally derived from sugarcane. For more information, please visit www.amyris.com.
Atalanta Rafferty. RF|Binder
SEATTLE – (December 10, 2019) – BP and Arzeda, the Protein Design Company™, are pleased to announce they have entered a second extended collaboration agreement for developing a bio-process for production of a renewable chemical of high strategic and industrial interest to BP.
After successful completion of the first phase of the project, the companies have chosen to enter the second phase with the aim to accelerate progress towards commercialization of the target chemical by building on the two companies complementary technologies and core competencies. Arzeda reached a major deliverable in the previous engagement, which set the stage for BP to move to this extended agreement.
Arzeda is excited to again be working with a leading energy and chemical company with a commitment to low-carbon solutions that contribute to a more sustainable future. Bringing to market bio-based products require simultaneous advances in multiple technologies, including the key catalysts, or enzymes. Arzeda’s protein design technology, Archytas™ is uniquely positioned to enable improved enzymes that drive the production of new products with attractive performance and economic value.
Alexandre Zanghellini, Arzeda’s CEO, commented, “A returning partner is a tremendous validation of our technology and the collective effort of the Arzeda and BP teams. We look forward to continue building value for BP and the next equally fruitful collaboration!”
Arzeda is harnessing the power of computational protein design to build novel enzymes and discover new pathways that enable cost effective, sustainable production of value-added specialty chemicals and ingredients. In partnership with Fortune 500 companies and industrial leaders, the company has developed a portfolio of enzymes that increase the efficiency, robustness and diversity of biological processes. Our proprietary pathway design software unlocks new opportunities for specialty chemicals, advanced materials and health and nutrition products that would otherwise be impossible to exploit.
More information is available at www.arzeda.com.
SEATTLE – (April 15, 2019) –Arzeda, the Protein Design Company™, has been featured in GeekWire: Inside Arzeda's synthetic biology lab, where industrial ingredients are brewed like beer.
SEATTLE – (April 6, 2019) –Arzeda, the Protein Design Company™, has been featured in the April 6th issue of The Economist's Technology Quarterly on synthetic biology.
Arzeda continues to climb the annual rankings of world’s most widely read biofuels and biobased chemicals daily journal
SEATTLE and SAN FRANCISCO – (November 14, 2018) –Arzeda, the Protein Design Company™, has been recognized for the third time as among the top companies in the advanced bioeconomy in the annual rankings by Biofuels Digest, the world’s most widely-read bioeconomy daily. Arzeda was ranked Number 5 in this year’s 40 Hottest Technologies in the Advanced Bioeconomy list, one step above its number 6 ranking in 2017. Arzeda ranked number 27 on the list in 2016.
SEATTLE and SAN FRANCISCO – (October 2, 2018) –Arzeda, The Protein Design Company™, and BP announced a collaboration to develop a process for producing a renewable chemical with broad applications.
SEATTLE and SAN FRANCISCO – (October 3, 2017) –Arzeda Corp, “The Protein Design Company™,” and TeselaGen Biotechnology Inc., a software company providing automated DNA design solutions with it’s Synthetic Evolution™ software platform, today announced that Arzeda will license TeselaGen’s proprietary cloud-based informatics solution and collaborate to extend TeselaGen’s state-of-the-art biological design automation platform.
Technology scale-up will unlock production of proteins that create sustainable stain-resistant paint, stronger Plexiglas, next-generation sweeteners, and purpose-built molecules that don’t yet exist
SEATTLE, (July 20, 2017) Arzeda, The Protein Design Company™, today announced that it had raised $12 million in a Series A round of funding led by OS Fund and including Bioeconomy Capital and Sustainable Conversion Ventures, as well as a follow-on investment from Arzeda’s seed investor, WRF Capital. Arzeda’s board will be expanded to include Jeff Klunzinger, Co-Founder at OS Fund.
SEATTLE (April 20, 2016) Gen9 and Arzeda today announced an agreement for the supply of megabase quantities of synthetic DNA that will enable Arzeda to accelerate development of novel molecules for its own products as well as those of its partners. The collaboration is part of Gen9’s MAP program, designed to provide industrial users of synthetic DNA with access to game-changing economics for synthetic DNA.
SEATTLE and EMERYVILLE, Calif. (March 21, 2016) Zymergen and Arzeda announced today a multi-year agreement to develop strains and processes to manufacture novel, high utility molecules and materials utilizing Arzeda’s pathway and enzyme design and Zymergen’s strain construction capabilities.